所在团队
杨崇广教授团队
研究方向
传染病流行病学及结核菌与宿主免疫
教育经历
2012-09至2017-06，南华大学，预防医学，本科
2017-09至2020-06，南方医科大学，公共卫生，硕士
2021-09至2025-06，山东大学，流行病与卫生统计学，博士
工作经历
2025-09至今，中山大学公共卫生学院（深圳）博士后
承担课题及科研项目
结核分枝杆菌感染的宿主免疫特征及调控机制研究，国家重点研发计划（2022-2025，参与，在研）
自然杀伤细胞在结核抵抗者产生中的作用机制，广东省自然科学基金面上项目（2023-2025，参与，在研）
代表性文章
- Zhang F#, Yang Z#, Geng X, Dong Y, Li S, Yao C, Shang Y, Ren W, Liu R, Kuang H, Li L, Pang Y. Using Machine Learning Methods to Predict Early Treatment Outcomes for Multidrug-Resistant or Rifampicin-Resistant Tuberculosis to Enhance Patient Cure Rates: Development and Validation of Multiple Models. J Med Internet Res. 2025, 27:e69998.
- Zhang F#, Dong Y#, Yang Z#, Guo C, Zhang X, Shang Y, Li L, Gao M, Pang Y. Pomalidomide promotes macrophage control of Mycobacterium tuberculosis via enhancing HDAC6-mediated autophagy. Int Immunopharmacol. 2025, 158:114831.
- Zhang F, Zhang Y, Yang Z, Liu R, Li S, Pang Y, Li L. The impact of maximum cross-sectional area of lesion on predicting the early therapeutic response of multidrug-resistant tuberculosis. J Infect Public Health. 2025, 18(2):102628.
- Jing W#, Zhang F#, Shang Y#, Shi W, Yao C, Zhang X, Chu N, Lu J, Yuan J. Deciphering the possible role of MmpL7 efflux pump in SQ109 resistance in Mycobacterium tuberculosis. Ann Clin Microbiol Antimicrob. 2024, 23(1):87.
- Zhang F#, Zhang F#, Dong Y, Li L, Pang Y. New Insights into Biomarkers for Evaluating Therapy Efficacy in Pulmonary Tuberculosis: A Narrative Review. Infect Dis Ther. 2023, 12(12):2665-2689.
- Zhang F#, Yu S#, Chai Q#, Wang J#, Wu T, Liu R, Liu Y, Liu CH, Pang Y. HDAC6 contributes to human resistance against Mycobacterium tuberculosis infection via mediating innate immune responses. FASEB J. 2021, 35(11):e22009.
- Huo F#, Zhang F#, Xue Y, Shang Y, Liang Q, Ma Y, Li Y, Zhao L, Pang Y. Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene. Int J Infect Dis. 2020, 92:241-246.
